Belite Bio, Inc. ADR Insider Trading
BLTE
Insiders sold $41M and bought nothing on the open market.
93% of the selling was scheduled in advance under 10b5-1 plans. Chief Medical Officer Hendrik Peter Scholl sold $1.45M on Jun 18, 40% of their stake, outside a plan. No executive or director has bought shares on the open market in the last two years.
Get an email when BLTE's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12 | Hendrik Peter Scholl Chief Medical Officer | Sold10b5-1 plan 4 parts | 2,000 | $165.99 average | 332K | 14% | Form 4 |
| Oct 1 | Hendrik Peter Scholl Chief Medical Officer | Sold10b5-1 plan 8 parts | 500 | $165.32 average | 83K | 3.3% | Form 4 |
| Sep 4 – 8 | Yu-Hsin Lin Chief Executive Officer | Sold10b5-1 plan 19 parts | 100,435 | $190.00 average | $19.1M | 59% | Form 4 |
| Sep 4 – 8 | Hao-Yuan Chuang Chief Financial Officer | Sold10b5-1 plan 19 parts | 67,395 | $189.98 average | $12.8M | 72% | Form 4 |
| Aug 12 | Hao-Yuan Chuang Chief Financial Officer | Sold10b5-1 plan 2 parts | 367 | $180.35 average | 66K | 0.4% | Form 4 |
| Aug 12 | Yu-Hsin Lin Chief Executive Officer | Sold10b5-1 plan 2 parts | 365 | $180.35 average | 66K | 0.2% | Form 4 |
| Jun 18 | Hendrik Peter Scholl Chief Medical Officer | SoldNo plan 5 parts | 10,000 | $145.24 average | $1.45M | 40% | Form 4 |
| Jun 16 | Hendrik Peter Scholl Chief Medical Officer | SoldNo plan 8 parts | 10,000 | $140.57 average | $1.41M | 29% | Form 4 |
| May 7 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 4 parts | 666 | $153.21 average | 102K | 100% | Form 4 |
| May 6 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 6 parts | 1,000 | $153.84 average | 154K | 60% | Form 4 |
| May 5 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 6 parts | 1,000 | $155.50 average | 156K | 38% | Form 4 |
| May 4 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 5 parts | 1,000 | $155.64 average | 156K | 27% | Form 4 |
| May 1 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 8 parts | 1,000 | $155.78 average | 156K | 21% | Form 4 |
| Apr 30 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 4 parts | 1,000 | $156.97 average | 157K | 18% | Form 4 |
| Apr 29 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 5 parts | 1,000 | $155.82 average | 156K | 15% | Form 4 |
| Apr 28 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 9 parts | 1,000 | $159.16 average | 159K | 13% | Form 4 |
| Apr 27 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 5 parts | 1,000 | $162.64 average | 163K | 12% | Form 4 |
| Apr 24 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 6 parts | 1,000 | $159.56 average | 160K | 10% | Form 4 |
| Apr 23 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 6 parts | 1,000 | $166.28 average | 166K | 9.4% | Form 4 |
| Apr 22 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 9 parts | 1,000 | $170.39 average | 170K | 8.6% | Form 4 |
| Apr 21 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 5 parts | 1,000 | $166.00 average | 166K | 7.9% | Form 4 |
| Apr 20 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 7 parts | 1,000 | $163.60 average | 164K | 7.3% | Form 4 |
| Apr 17 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 6 parts | 1,000 | $161.63 average | 162K | 6.8% | Form 4 |
| Apr 16 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 7 parts | 1,000 | $160.38 average | 160K | 6.4% | Form 4 |
| Apr 15 | Nathan L. Mata Chief Scientific Officer | Sold10b5-1 plan 5 parts | 1,000 | $168.30 average | 168K | 6.0% | Form 4 |
| Apr 9 | Yu-Hsin Lin Chief Executive Officer | Sold10b5-1 plan 4 parts | 9,200 | $181.45 average | $1.67M | 5.1% | Form 4 |
| Apr 9 | Wan-Shan Chen Director | Sold10b5-1 plan | 1,100 | $180.43 | 198K | 11% | Form 4 |
| Apr 9 | Hao-Yuan Chuang Chief Financial Officer | Sold10b5-1 plan 4 parts | 6,200 | $181.50 average | $1.13M | 6.2% | Form 4 |
- Nov 1210b5-1 planHendrik Peter SchollChief Medical Officer · sold 2,000 at avg $165.99332K14% of stake
- Oct 110b5-1 planHendrik Peter SchollChief Medical Officer · sold 500 at avg $165.3283K3.3% of stake
- Sep 4 – 810b5-1 planYu-Hsin LinChief Executive Officer · sold 100,435 at avg $190.00$19.1M59% of stake
- Sep 4 – 810b5-1 planHao-Yuan ChuangChief Financial Officer · sold 67,395 at avg $189.98$12.8M72% of stake
- Aug 1210b5-1 planHao-Yuan ChuangChief Financial Officer · sold 367 at avg $180.3566K0.4% of stake
- Aug 1210b5-1 planYu-Hsin LinChief Executive Officer · sold 365 at avg $180.3566K0.2% of stake
- Jun 18No planHendrik Peter SchollChief Medical Officer · sold 10,000 at avg $145.24$1.45M40% of stake
- Jun 16No planHendrik Peter SchollChief Medical Officer · sold 10,000 at avg $140.57$1.41M29% of stake
- May 710b5-1 planNathan L. MataChief Scientific Officer · sold 666 at avg $153.21102K100% of stake
- May 610b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $153.84154K60% of stake
- May 510b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $155.50156K38% of stake
- May 410b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $155.64156K27% of stake
- May 110b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $155.78156K21% of stake
- Apr 3010b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $156.97157K18% of stake
- Apr 2910b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $155.82156K15% of stake
- Apr 2810b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $159.16159K13% of stake
- Apr 2710b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $162.64163K12% of stake
- Apr 2410b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $159.56160K10% of stake
- Apr 2310b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $166.28166K9.4% of stake
- Apr 2210b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $170.39170K8.6% of stake
- Apr 2110b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $166.00166K7.9% of stake
- Apr 2010b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $163.60164K7.3% of stake
- Apr 1710b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $161.63162K6.8% of stake
- Apr 1610b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $160.38160K6.4% of stake
- Apr 1510b5-1 planNathan L. MataChief Scientific Officer · sold 1,000 at avg $168.30168K6.0% of stake
- Apr 910b5-1 planYu-Hsin LinChief Executive Officer · sold 9,200 at avg $181.45$1.67M5.1% of stake
- Apr 910b5-1 planWan-Shan ChenDirector · sold 1,100 at $180.43198K11% of stake
- Apr 910b5-1 planHao-Yuan ChuangChief Financial Officer · sold 6,200 at avg $181.50$1.13M6.2% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Biotechnology · Pick stocks to compare with BLTE
Held by ETFs
BLTE is in 7 US ETFs. The largest of them, with BLTE's weight in each:
SPDR Portfolio Emerging Markets ETFSPEM0.03%of the fund
Fidelity Nasdaq Composite Index ETFONEQ0.01%of the fund
- APActivePassive International Equity ETFAPIE0.06%of the fund
SPDR S&P China ETFGXC0.11%of the fund
- EHEven Herd Long/Short ETFEHLS0.33%of the fund
- BBVirtus Biotech Clinical Trials ETFBBC0.77%of the fund
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BLTE
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.